Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.89 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.80 |
| ▸ | ATM | Q13315 | 1/20 | 0.80 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrylammonium SCHEMBL1933478 | 1.00 | TSHR (0.89) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL23528606 | 1.00 | TSHR (0.89) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL5484926 | 0.95 | TSHR (0.80) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL5484929 | 0.94 | TSHR (1.00) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL16267 | 0.94 | — | — | |
| Tetrylammonium SCHEMBL4078612 | 0.94 | TSHR (1.00) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL11162171 | 0.89 | TSHR (0.89) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL333139 | 0.89 | TSHR (0.89) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL21268035 | 0.89 | TSHR (0.89) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL3215591 | 0.89 | TSHR (0.89) | TSHRNFKB1KCNA1KDM4EPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015051141-A1 | METHODS FOR PREPARATION OF FLUORINATED SULFUR-CONTAINING COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2015-04-09 | — | — | WO | claimed |
| CN-109643822-B | Nonaqueous electrolyte composition comprising fluorinated sulfone | 索尔维公司 | 2023-04-28 | — | — | CN | disclosed |
| US-11374260-B2 | Nonaqueous electrolyte compositions comprising fluorinated sulfones | SYENSQO SA (BE) | 2022-06-28 | — | — | US | disclosed |
| EP-3465811-B1 | NONAQUEOUS ELECTROLYTE COMPOSITIONS COMPRISING FLUORINATED SULFONES | SOLVAY (BE) | 2021-09-29 | — | — | EP | disclosed |
| US-20200321657-A1 | NONAQUEOUS ELECTROLYTE COMPOSITIONS COMPRISING FLUORINATED SULFONES | SYENSQO SA (BE) | 2020-10-08 | — | — | US | disclosed |
| EP-3013808-B1 | ISOTHIAZOLINE COMPOUNDS SUBSTITUTED WITH A CARBOBICYCLIC GROUP | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3013807-B1 | NAPHTHYL-SUBSTITUTED ISOTHIAZOLINE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-105473584-B | Thiophene-or furan-substituted isothiazoline compounds | 勃林格殷格翰动物保健美国公司 | 2020-01-31 | — | — | CN | disclosed |
| US-10327446-B2 | Naphthyl- or isoquinolinyl-substituted isothiazoline compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-06-25 | — | — | US | disclosed |
| CN-109643822-A | Non-aqueous electrolyte composition comprising fluorinated sulfone | 索尔维公司 | 2019-04-16 | — | — | CN | disclosed |
| EP-1816120-A1 | Aminonitrile production | INVISTA Technologies S.à.r.l. (US) | 2007-08-08 | — | — | EP | disclosed |
| CN-1273439-C | Aminonitrile production | INVISTA TECH SARL (CH) | 2006-09-06 | — | — | CN | disclosed |
| CN-1556789-A | Aminonitrile production | 纳幕尔杜邦公司 | 2004-12-22 | — | — | CN | disclosed |
| EP-1434758-A1 | AMINONITRILE PRODUCTION | INVISTA Technologies S.à.r.l. (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003029192-A1 | AMINONITRILE PRODUCTION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| US-6455723-B1 | Aminonitrile production | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-09-24 | — | — | US | disclosed |
| WO-1997015086-A1 | REVERSIBLE HIGH ENERGY CAPACITY METAL-SULFUR BATTERY AND METHOD OF MAKING SAME | EDLING JACK V (US) | 1997-04-24 | — | — | WO | disclosed |
| US-5506072-A | DURABILITY, PERFORMANCE | Griffen, Eric B. (US) | 1996-04-09 | — | — | US | disclosed |
| US-5076358-A | Petroleum recovery with organonitrogen thiocarbonates | UNION OIL COMPANY OF CALIFORNIA (US) | 1991-12-31 | — | — | US | disclosed |
| US-3974066-A | Removal of oxygen from petroleum charge stocks | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10327446-B2 | Naphthyl- or isoquinolinyl-substituted isothiazoline compounds | IPO5, SNX1, IPO9 | TSHR 4255/4885NFKB1 604/4885KCNA1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.